Condition
PANS
Total Trials
5
Recruiting
2
Active
2
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
1Total
P 2 (1)
Trial Status
Completed3
Recruiting2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06811935RecruitingPrimary
PEDI Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcus Study
NCT06818656Completed
The Unhide™ Project: Economic Impact Study of IVIG Treatment for PANS
NCT04382716CompletedPrimary
Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS): Clinical Characterization and Prospective Course
NCT01617083Phase 2CompletedPrimary
Antibiotic Treatment Trial for the PANDAS/PANS Phenotype
NCT02889016Recruiting
Neurobiologic, Immunologic, and Rheumatologic Markers in Youth With PANS
Showing all 5 trials